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Abstract 13 
There are many methods for quantifying the concentration of a specific (target) protein in 14 
a sample, but current techniques are technically challenging or do not easily lend themselves to 15 
normalizing measured protein concentrations against the total amount of protein in the sample. 16 
Here, we describe a microbead-based assay for quantifying specific protein concentration(s) 17 
that is high-throughput, inexpensive, relatively simple to carry out, and which intrinsically 18 
incorporates normalization against the total protein content in each sample. This assay, which 19 
we term the FRANC assay, exploits high affinity biotin-streptavidin binding to couple sample 20 
proteins to streptavidin-labeled magnetic microbeads. Proteins so attached are then probed with 21 
one or more antibodies, followed by labeling of all proteins on the microbead with a fluorescent 22 
dye, and flow cytometry-based analysis. The FRANC assay demonstrates detection limits for 23 
target proteins in the single femtogram range, with an operating range up to as much as 10 24 
nanograms of target protein. When quantifying total protein amount, the variation between 25 
different protein samples was similar to that of the bicinchoninic acid (BCA) assay. Finally, 26 
normalization of target protein concentrations resulted in at least an 80% reduction in variability 27 
as compared to non-normalized measurements. We conclude that the FRANC assay offers 28 
attractive advantages over current methods of quantifying specific protein(s) in complex 29 
samples.  30 
Introduction 31 
Quantifying the concentration of specific (target) proteins in a complex sample is an 32 
essential analytical technique for many biomedical applications. Samples typically consist of 33 
lysed tissue or other complex mixtures of multiple proteins1, and current quantification methods 34 
employ antibody-based labelling and fluorescent, luminescent, or colorimetric determination of 35 
protein amounts2,3. For example, western blotting is commonly used for protein quantification4,5; 36 
it has the advantage of size separation by molecular weight, but the associated protein transfer 37 
can be technically challenging and slow 2,6,7. Alternatively, enzyme-linked immunosorbent 38 
assays (ELISA), fluorescent microbead arrays, and related multiplex assays are now commonly 39 
used, as they allow for higher throughput 8-10. The disadvantage of such assays, however, is 40 
limited flexibility, since kits containing validated antibody pairs for each protein of interest are 41 
often required.  42 
An important consideration in all analytical techniques is sample normalization, i.e. the 43 
reporting of the concentration of the specific protein of interest in relation to levels of one or 44 
more reference proteins. Normalization accounts for user errors such as pipetting, as well as 45 
sample-to-sample variability, and is routinely performed in Western blot analysis by normalizing 46 
to a single reference protein (e.g. GAPDH, β-actin)11-13. While single reference proteins are 47 
sufficient for normalization in certain applications, reference protein amounts often vary between 48 
samples, making a single reference protein inadequate for sample normalization in many 49 
situations14,15. As a result, total protein-based normalization has been incorporated into Western 50 
blot analysis using different fluorescent or colorimetric total protein stains16-19. ELISAs and 51 
multiplex assays, however, are not well suited to total protein-based normalization. 52 
Here, we describe a microbead-based platform to quantify the concentration of one or 53 
more specific (target) proteins within a sample. It combines the beneficial features of multiplex 54 
assays with robust normalization against the total concentration of protein within each assayed 55 
sample. We refer to this as the FRANC assay (Flexible, Robust Assay for quantification and 56 
Normalization of target protein Concentration).  We first describe the technology and then 57 
characterize the performance of the FRANC assay.  58 
Results 59 
Overview of FRANC Assay 60 
The assay proceeds in four main steps. First, all proteins in a sample are attached to the 61 
surface of a microbead (Figure 1). Second, the microbeads are exposed to one or more 62 
fluorescently tagged antibodies to detect target proteins of interest. Third, carbodiimide 63 
crosslinking is used to conjugate fluorescent dye to carboxylic acid groups in all proteins on the 64 
surface of the microbeads. Finally, the microbeads are analyzed by flow cytometry to detect 65 
both the fluorescent signal from bound antibodies and the dye signal from all labelled proteins. 66 
Signal normalization can then be performed by expressing the antibody-specific signal as a ratio 67 
relative to the signal from all labelled proteins. For ease of sample handling, magnetic 68 
microbeads are used in the FRANC assay, since they can be quickly removed from solutions 69 
without sample loss using a 96-well magnetic plate (see verification in Supplementary Figure 1). 70 
 71 
Figure 1. Schematic Overview of the FRANC Assay Process. (A) Protein samples are (B) 72 
biotinylated and (C) conjugated to magnetic microbeads through biotin-streptavidin interactions. 73 
(D) Microbeads are then exposed to fluorescently-labelled antibodies to tag specific proteins of 74 
interest, and (E) fluorescently labeled to determine total protein amount, which is required to 75 
normalize against protein amount. (F-H) Microbeads are analyzed by flow cytometry. (F) 76 
Forward vs. side scatter plots are used to distinguish singlet microbeads from aggregates. Both 77 
(G) antibody and (H) total protein signals are detected for each sample-conjugated microbead 78 
set.  79 
Protein Biotinylation 80 
There are several practical considerations that are important to the robust performance 81 
of the FRANC assay. For example, when attaching sample proteins to the microbead, it is 82 
appealing to simply allow proteins to adsorb onto the microbead surface, since this would permit 83 
great flexibility in antibody labeling and subsequent steps. However, the affinity of such an 84 
attachment varies from one protein to another, so that a simple adsorption strategy would result 85 
in a biased protein sample on the microbead surface. To avoid this problem, we used biotin-86 
streptavidin binding to conjugate proteins to the microbeads, since the high affinity of the biotin-87 
streptavidin bond overcomes protein-to-protein differences in passive adsorption. This required 88 
that protein samples be biotinylated, and that microbeads be coated with streptavidin prior to 89 
exposure to the sample.  90 
We biotinylated protein samples by using sulfo-NHS-LC-Biotin to modify protein primary 91 
amine groups (Figure 2A). To characterize the performance of this process, a range of 92 
protein:biotin mass ratios was tested, and signal from antibody-based labeling was measured 93 
for each sample. We used rabbit serum as the protein sample and detected the amount of rabbit 94 
IgG in this sample using a suitable fluorescently conjugated antibody. The operating range 95 
(defined as the linear range [R2 > 0.9] of logarithmically-transformed antibody signal vs. the 96 
corresponding logarithmically-transformed sample protein amounts; see methods) spanned 4 or 97 
more dilution steps for protein:biotin mass ratios above 32 (Figure 2B). On the other hand, 98 
protein:biotin mass ratios less than 32 did not demonstrate an acceptable operating range. In 99 
addition, the dynamic output ranges (DOR, defined as the ratio between maximum antibody 100 
signal across the operating range to antibody signal for controls [no protein added]; see 101 
methods) were similar for protein:biotin mass ratios from 32 to 512, but were lower for a 102 
protein:biotin mass ratio of 2048 (Figure 2C). Given that protein:biotin mass ratios between 32 103 
and 512 produced wide operating ranges and similar DORs, a protein:biotin mass ratio of 32 104 
was selected for future testing since it most closely matched previously-used protein:biotin mass 105 
ratios and required less sample protein20. 106 
 107 
Figure 2. Effect of biotin labeling and protein-microbead incubation time on antibody 108 
labeling. (A) Overview of biotinylation of sample protein with sulfo-NHS-LC biotin through 109 
primary amine group modification21. (B) Effect of protein:biotin mass ratio on antibody labeling of 110 
IgG in a sample of rabbit serum. The heat map provides a pictorial representation of how 111 
labeling intensity varies with protein amount for each protein:biotin mass ratio, across the 112 
assay’s operating range (R2 > 0.9; see methods). Conditions selected for the FRANC assay are 113 
denoted by the green star. Grey squares indicate conditions falling outside the assay’s 114 
operating range. (C) The dynamic output range (DOR, see methods) vs. protein:biotin mass 115 
ratio. (D) Effect of protein-microbead incubation duration on antibody labeling of IgG in a sample 116 
of rabbit serum. The heat map provides a representation of how labeling intensity varies with 117 
protein amount for 30, 60, 120 minutes and overnight incubations of rabbit serum with 118 
microbeads. (E) The dynamic output range vs. protein-microbead incubation duration. For 119 
panels A and C, error bars denote standard deviation. n = 3 technical replicates for each dilution 120 
step. Statistical significance (p < 0.05) as indicated was determined by one-way ANOVA, post-121 
hoc Tukey analysis. 122 
Protein-Microbead Incubation Time 123 
Next, we determined how assay results were affected by the duration over which 124 
biotinylated proteins were incubated with streptavidin-coated magnetic microbeads. Using 125 
manufacturer’s recommendations, we considered incubation durations from 30 minutes to 126 
overnight. Antibody labeling of rabbit IgG in a sample of rabbit serum showed similar operating 127 
ranges across all tested incubation durations (Figure 2D). DORs were calculated for each 128 
incubation duration, with 30 minutes and overnight showing slightly higher ranges than other 129 
incubation durations (Figure 2E). However, differences between incubation durations were 130 
minimal, suggesting there is little advantage to extending incubation beyond 30 minutes. We 131 
thus selected a 30-minute protein-microbead incubation duration for future tests.  132 
Antibody-based Fluorescent Labeling 133 
Parameters for antibody-based labeling were next assessed, again using an antibody 134 
against rabbit IgG in a rabbit serum sample. The first parameter considered was antibody 135 
concentration: we tested concentrations ranging from 10ug/mL (a dilution factor [DF] of 50 for 136 
this antibody) to as little as 5ng/mL (DF of 10240). As expected, more antibody resulted in 137 
stronger signal; however, the extent of the operating ranges for antibody-labeling signal vs. 138 
sample protein amount were similar for each tested concentration (Figure 3A). Differences were 139 
more evident when assessing DORs (Figure 3B). At low antibody concentrations (2000 DF and 140 
higher) the DOR was poor, while at high antibody concentrations (100 DF and 50 DF), the DOR 141 
was also poor due to increased background signal in controls with no sample protein. 142 
Intermediate antibody concentrations of 200, 500, and 1000 DF yielded similar DORs. Due to 143 
the sharp decline in signal beyond the 1000-fold DF, we selected a 500-fold antibody dilution 144 
factor (antibody concentration of 1 µg/mL) for subsequent testing.  145 
Another important parameter in antibody labeling is the duration of the antibody 146 
incubation with sample protein on microbeads. The antibody concentration experiments 147 
described above were performed using 30 minute incubation durations. Additional experiments, 148 
using a 500-fold antibody dilution factor (1 µg/mL for this antibody), were performed for 60 and 149 
120 minute incubations. Overall, the operating range was similar for all incubation durations 150 
(Supplementary Figure 2A) and the DOR was minimally impacted by incubation duration 151 
(Supplementary Figure 2B). As a result, we chose to continue using 30 minutes as the preferred 152 
duration for antibody incubation.  153 
Total Protein Fluorescent Labeling 154 
A key aspect of the FRANC assay is the ability to measure the total amount of protein 155 
conjugated to microbeads, and thus we investigated a number of parameters for their impact on 156 
the fluorescent labelling of total protein on beads. Carbodiimide-based conjugation of protein 157 
with dye was performed in two steps: (1) carboxylic acid activation by EDC and sulfo-NHS, and 158 
(2) fluorescent labeling with an amine reactive dye (Figure 3C). Thus, we first assessed different 159 
EDC concentrations, sulfo-NHS concentrations, and conjugation durations to determine how 160 
total protein signal depended on these parameters. Baseline parameter values, as determined 161 
from previous literature20, were found to work well and were selected as the preferred conditions 162 
for the FRANC assay (Supplementary Figure 3).  163 
For the second step, two primary amine-containing dyes were tested for total protein 164 
labeling: Alexa Fluor 488 Hydrazide and 4’(aminomethyl)fluorescein (AMF). Initial experiments 165 
utilized the hydrazide dye, but AMF was more cost-effective, particularly at higher dye 166 
concentrations. One hydrazide concentration (5 µg/ml) and 3 AMF concentrations (5 µg/ml, 50 167 
µg/ml and 500 µg/ml) were tested immediately following carbodiimide exposure. We found that 168 
using AMF at concentrations of 50 and 500 µg/ml resulted in similar operating ranges for total 169 
protein fluorescent signal (Supplementary Figure 4A). While there was a greater DOR using 500 170 
µg/ml of AMF, the results were more variable (Supplementary Figure 4B). Given the higher 171 
variability and cost associated with using 500 µg/ml of AMF, 50 µg/ml of AMF was selected as 172 
the optimal dye type and concentration. Fluorescent dye incubation duration was next 173 
assessed. Initially, a 120 minute incubation time was used, but 30, 60 and 240 minutes were 174 
also assessed using 50 µg/ml of AMF dye. The widest operating range was evident for 120 175 
minutes, while 30 and 240 minutes did not result in a suitable operating range across tested 176 
sample protein amounts (Figure 3D). DOR range was similar for 60 and 120 minutes (Figure 177 
3E). In view of its favorable operating range, 120 minutes was thus selected as the preferred 178 
incubation duration.   179 
 180 
Figure 3. Effect of antibody concentration and total protein fluorescent dye incubation 181 
duration on FRANC assay performance. (A,B) Microbeads bound to rabbit serum were 182 
incubated with different antibody concentrations (antibody dilution factors from 50 to 10,000-fold 183 
from a starting anti-rabbit IgG antibody concentration of 0.5 mg/mL). (A) Effect of antibody 184 
concentration on antibody labeling of rabbit IgG in a sample of rabbit serum. The heat map 185 
provides a pictorial representation of how labeling intensity varies with antibody dilution factor, 186 
across the determined operating range (R2 > 0.9; see methods). Conditions selected for the 187 
FRANC assay are denoted by green star. (B) The dynamic output range (DOR, see methods) 188 
vs. antibody concentration. Error bars denote standard deviations (n=3 technical replicates). (C) 189 
Diagram of carbodiimide conjugation of carboxylic acid functional groups in protein with EDC 190 
and sulfo-NHS. (D) Effect of AMF dye (50µg/ml) incubation time (30, 60, 120, and 240 minutes) 191 
on total protein labeling of a rabbit serum sample. The heat map is interpreted as in panel A; we 192 
use blue color coding to indicate that this panel refers to total protein labeling rather than 193 
antibody-based labeling of a target protein. Grey squares in the heat map indicate conditions 194 
falling outside the operating range. (E) The dynamic output range vs. total protein dye 195 
incubation time (n=2 technical replicates). Statistical significance (p < 0.05) was determined by 196 
one-way ANOVA, post-hoc Tukey analysis. 197 
Analytical Sensitivity of the Assay 198 
After determining suitable values for key parameters of the FRANC assay, overall assay 199 
performance was characterized, beginning with the assay’s analytical sensitivity. We first carried 200 
out tests with two different recombinant proteins having different antibody labeling chemistry. 201 
Specifically, recombinant TNF-α was biotinylated and incubated with microbeads and was then 202 
detected with an anti-TNF-α antibody conjugated to a fluorophore (PE-Cy7). This resulted in an 203 
analytical sensitivity of 12 picograms of TNF-α protein and an operating range of 12 pg - 12.5 ng 204 
(Figure 4A). Additionally, recombinant IL-1β was detected with a non-fluorescent primary 205 
antibody and a fluorescent secondary antibody in two separate steps, producing an analytical 206 
sensitivity of 5 femtograms (fg) and an operating range of 5 fg to 34 pg (Figure 4B). The 207 
improved analytical sensitivity when using a secondary antibody is consistent with secondary 208 
labeling typically yielding more fluorophores per epitope. 209 
Variability of total protein labeling for different protein samples 210 
We next assessed how total protein labeling varied for different sample types, since it is 211 
imperative that the total protein labeling not be heavily impacted by protein sample composition. 212 
In testing the FRANC assay, it was necessary to quantify total protein concentrations in samples 213 
using an independent protein assay. For this purpose, we chose the widely-used BCA assay22. 214 
For this aspect of testing, we used six samples: three different sera (rabbit, goat, and mouse), 215 
primary mesenchymal stem cell (MSC) lysates, and cell lysates from untreated and from 216 
experimentally-treated HT-1080 immortalized cells. We plotted FRANC total protein signal (or 217 
BCA assay absorbance) vs. each sample’s protein loading amount and computed the slope of 218 
each plot over the operating region. If the assays were insensitive to protein sample 219 
composition, all slopes would be identical; in practice, this is not the case and we therefore 220 
computed a coefficient of variation for the slopes over the six samples as a measure of the 221 
assay’s sensitivity to sample composition. When using a linear regression methodology 222 
(conventional for the BCA assay; see methods) the coefficient of variation was lower with the 223 
FRANC assay (0.72 FRANC vs. 0.92 BCA). Comparing the slopes for the individual samples, 5 224 
of the 6 samples had similar slopes for both assays, suggesting the FRANC assay performed 225 
similar to, or slightly better than, the BCA assay (Supplementary Figure 5A).  226 
An alternative analysis approach is to log-transform the protein concentration and assay 227 
signal data (see methods) and regress this transformed data; doing so reduced the coefficient of 228 
variation for the slopes to 0.38 for the FRANC assay and 0.19 for the BCA assay. When 229 
comparing the log-transformed analysis approach to the more conventional direct approach,   230 
the FRANC assay performed similarly to the BCA assay for each sample (Supplementary 231 
Figure 5B).  Interestingly, log-transformation reduced the coefficient of variation for the BCA 232 
method more than it did for the FRANC assay, likely due to the higher variability present at very 233 
low protein amounts in the FRANC assay’s operating range (less than 0.1ng protein amount). 234 
These protein levels were not detectable with the BCA assay, which showed an analytical 235 
sensitivity of approximately 1µg. In conclusion, while variation between samples was apparent 236 
in determination of total protein levels for both the FRANC and BCA assays, the performance of 237 
these two assays was comparable, with slightly higher sample-to-sample variability in the 238 
FRANC assay being offset by greater sensitivity. 239 
 240 
Figure 4. Determination of the analytical sensitivity (lower detection limit) for antibody 241 
labeling. Antibody-specific fluorescent label vs. protein amount for (A) TNF-α recombinant 242 
protein detected by PE-Cy7 fluorescently-conjugated primary antibody and (B) IL-1β 243 
recombinant protein with unlabeled primary antibody followed by PE fluorescently-conjugated 244 
secondary antibody. The operating range is shown by a regression fit (solid line) to the log-245 
transformed data. Error bars denote standard deviations (n=3 technical replicates for each, in 246 
some cases, error bars cannot be seen because the error is smaller than the data point).  247 
 248 
Total Protein Normalization 249 
Finally, we evaluated the ability of the FRANC assay to robustly normalize antibody 250 
signal by the total protein signal. We detected rabbit IgG within a sample of rabbit serum using 251 
AMF dye for simultaneous total protein labeling. As expected, the antibody and total protein 252 
signals increased with sample protein amount (Figure 5A), with these two signals increasing at 253 
comparable rates, as required for normalization. When the antibody signal was normalized by 254 
the total protein signal, the ratio was relatively constant across sample protein amount, as 255 
desired (Figure 5A). This behavior was quantified by the slope of plots of antibody signal (or 256 
antibody signal normalized by total protein signal) vs. sample protein amount, where slope 257 
values closer to zero suggest less antibody-labeling signal variability over the operating range. It 258 
was observed that normalization reduced these slopes from 0.74 to 0.12 (Figure 5B). For 259 
comparison, antibody signal was normalized to loaded rabbit serum sample protein amount, as 260 
determined by the conventional BCA assay. This resulted in a slope of -0.25, which is further 261 
from the desired value of zero than the FRANC assay’s total protein normalization methodology. 262 
In conclusion, the FRANC assay’s total protein-based normalization was effective at accounting 263 
for loading variability and user error that cannot be accounted for when relying on protein 264 
quantification that is not fully integrated into the assay.  265 
 266 
Figure 5. Normalization by total protein reduces assay variability. (A) A rabbit serum 267 
sample was probed with fluorescently-tagged anti-rabbit IgG, followed by measurement of total 268 
protein (n=4 technical replicates). Normalized antibody signals were calculated by dividing 269 
antibody signal by respective total protein signal across the operating range. Operating range 270 
for antibody, total protein, and normalized antibody are shown (solid regression lines) on a log-271 
log plot of assay signal vs. sample protein amount. (B) Slope of regression to fluorescent signal 272 
vs. sample protein amount over the operating region for antibody signal, antibody signal 273 
normalized to total protein, and antibody signal relative to loaded sample protein amount, as 274 
determined by BCA assay (n=4 technical replicates). Error bars denote standard deviation. 275 
Statistical significance (p < 0.05) was determined by one-way ANOVA, post-hoc Tukey analysis. 276 
Discussion 277 
The FRANC assay we describe here provides a platform for quantification of specific 278 
(target) proteins within a complex mixture. The assay is capable of robustly accounting for 279 
sample variability through total protein normalization in a manner that is integrated with the 280 
overall assay. While western blotting can account for loading and sample variability with various 281 
normalization approaches, it is slow and technically challenging compared to other methods. 282 
Conversely, ELISA and multiplex assay-based protein quantification is much faster, but 283 
normalization is not intrinsically feasible within the assay, since only a subset of proteins in the 284 
sample (i.e. those recognized by “capture” antibodies on microbeads or well-plates) is assayed. 285 
Thus, there is a need for an improved method for quantifying specific (target) proteins within a 286 
sample. The FRANC assay we report here addresses these shortcomings by combining a 287 
microbead platform, which allows for high-throughput simple protein handling in multiplex 288 
assays, with total protein-based signal normalization.  289 
A key aspect of the FRANC assay is the use of biotin-streptavidin interactions for sample 290 
protein conjugation to microbeads. By conjugating biotin to primary amine groups in a protein 291 
sample using sulfo-NHS chemistry, we can exploit the strong affinity between biotin and 292 
streptavidin, ensuring that all proteins in a sample bind to the microbead surface with similar 293 
affinities, regardless of protein structure. This key step overcomes a limitation of passive surface 294 
adsorption 23-27, i.e. the differential affinity of different proteins to passively bind to microbeads. 295 
We tested a wide range of protein:biotin mass ratios and found that lower (i.e. more sensitive) 296 
protein detection limits were achievable when more biotin was added. However, this came at 297 
the cost of poorer antibody binding. This understanding allows assay flexibility depending on 298 
factors such as antibody affinity to the target protein, sample amounts, and the required assay 299 
sensitivity. Additionally, the biotinylation chemistry could be altered to bind other amino acid 300 
sequences 20 or even to bind only the N-terminus by modifying the incubation pH 28,29.  301 
The FRANC assay is compatible with traditional antibody-based fluorescent labeling of 302 
specific proteins of interest. After protein conjugation to microbeads, antibody labeling occurred 303 
with an incubation time of as short as 30 minutes, and with antibody concentrations as low as 304 
0.5 µg/mL. In addition, the FRANC assay is compatible with direct and indirect antibody 305 
labeling. While multiplex tests were not performed, the FRANC assay is also expected to be 306 
compatible with a wide range of fluorophores, including simultaneous multi-antibody labeling 307 
which is commonly performed with 10 or more probes in traditional flow cytometry 30. Although 308 
not observed in this study, it is possible that some antibody-antigen interactions could be 309 
inhibited due to the biotinylation of primary amine groups; if this were suspected, reducing the 310 
degree of sample biotinylation would be recommended. 311 
The final component of the FRANC assay is fluorescent labeling of the total protein 312 
attached to microbeads, essential for sample protein normalization. While single reference 313 
proteins are often used in western blot analysis for normalization, the relative concentrations of 314 
many reference proteins varies across experimental conditions12-14. Total protein labeling offers 315 
a more robust normalization method 17,18. For the FRANC assay, total protein labeling was 316 
performed by conjugating primary amine-containing fluorescent dyes to carboxylic acid groups. 317 
After determining the preferred concentrations for crosslinkers and fluorescent dye, we 318 
observed that the operating range for total protein signal approximately coincided with the 319 
operating range for antibody-specific labeling. Thanks to these similar operating ranges, 320 
normalization was possible by expressing antibody labeling relative to total protein labeling, 321 
which reduced the variability by approximately 6-fold. This is an extreme example to 322 
demonstrate the normalization capabilities of the FRANC assay, since practical assay 323 
applications would not use normalization over such a wide range of protein amounts, but would 324 
instead utilize normalization to account for loading error and slight quantification differences 325 
between replicates and sample types. This scenario was illustrated by the ability of the FRANC 326 
assay’s normalization approach to reduce variability to about half the variability observed when  327 
using total protein amounts determined separately from the BCA assay. Thus, robust signal 328 
normalization enhances assay quality and is an important feature of the FRANC assay.  329 
Total protein normalization is only useful if labeling of total protein content is consistent 330 
between different protein samples. We tested six different protein samples with the FRANC 331 
assay, and determined that the assay variability was very similar to that of the well-established 332 
BCA assay, which suggests that the total protein labeling approach is not heavily skewed by 333 
amino acid composition. However, this was true only when results were analyzed using 334 
traditional linear regression of assay signal vs. protein loading, commonly used with the BCA 335 
assay. Logarithmic transformation of the data decreased the variability of both assays, although 336 
the decrease was less impressive for the FRANC assay vs. the BCA assay, suggesting greater 337 
variability at lower total protein signals with the FRANC assay. If end-users required reduced 338 
variability for small protein amounts, different functional groups could be targeted, or brighter 339 
total protein fluorescent dyes utilized. Further improvements to total protein signal are possible 340 
by simultaneously combining multiple chemistries to detect multiple functional groups. 341 
Table 1. Overview of the performance of the normalized protein expression assay 342 
Specification Normalized Protein Expression Microbead Assay 
Normalization Capability 
Strong. Intrinsic to each assay sample for accounting for 
sample loading and other user errors 
Lower Detection Limit 
TNF-α + PE-Cy7 fluorescent primary antibody: ~24 pg            
IL-1β + unlabeled primary antibody + PE secondary antibody: 
0.2 fg 
Linear Operating Range  TNF-α : ~12 pg to ~12.5 ng            IL-1β: ~5 fg to ~34 pg 
High-Throughput Aspects 
Applicable to 96 or 384-well plate formats, multiplex 
fluorescent antibodies up to flow cytometer limitations 
Required Protein Sample 
Amount 
Less than 0.5 µg 
Overall Assay Procedure 
Time 
5 to 6 hours from protein sample to flow cytometric analysis 
Hands-on Time Approximately 1 hour 
Reagent Cost per Sample Approximately $3 per 12-step, single sample dilution curve 
Overall, the FRANC assay was attractive compared to conventional western blotting, 343 
ELISA, and multiplex assays, as summarized in Table 1. Sensitivity was found to be 12 344 
picograms protein for direct antibody labeling, which is comparable to ELISAs, multiplex assays, 345 
and conventional western blotting31,32. Indirect antibody labeling resulted in detection in femto- 346 
to picogram quantities, similar to recent advances in microfluidic western blotting that have also 347 
reported detection of femtogram quantities33. The FRANC assay requires approximately 5 to 6 348 
hours from start to finish, of which most time is “hands-off” incubations, leading to approximately 349 
1 hour of hands-on time. The cost of the required reagents and quantities needed per 96-well 350 
sample are modest, resulting in a cost of approximately $3 per 12-step, single sample dilution 351 
scheme. However, it is recommended that end-users confirm reagent concentrations and 352 
antibody dilutions for their specific application, which will affect the assay cost. In conclusion, 353 
the normalized protein expression microbead assay presented herein is an improved approach 354 
that integrates total protein labeling, important for assay normalization, with traditional 355 
fluorescent antibody-specific protein labeling.   356 
 357 
Methods and Materials 358 
Sample preparation and sourcing 359 
A variety of protein samples, representing a range of situations encountered in 360 
laboratory work, was used for testing the FRANC assay. Goat (LAMPIRE Biological 361 
Laboratories, Pipersville, PA, USA), rabbit (Gibco, Waltham, MA, USA) and mouse (Invitrogen, 362 
Waltham, MA, USA) sera were obtained commercially. Primary adipose-derived mesenchymal 363 
stem cells (Lonza, Basel, Switzerland) were grown to confluence and were then lysed using 364 
RIPA buffer (Thermo-Fisher, Waltham, MA, USA) supplemented with Halt protease inhibitors 365 
(Thermo-Fisher, Waltham, MA, USA). Similarly, immortalized HT-1080 fibrosarcoma cells 366 
(American Type Culture Collection, Manassas, VA, USA) were lysed without treatment or after 367 
24 hours of treatment with 25 ng/mL phorbol 12-myristate 13-acetate (PMA, MilliporeSigma, St. 368 
Louis, MO, USA)34. PMA is known to activate protein kinase C and alter downstream protein 369 
expression, such as matrix metalloproteinases34,35. Recombinant TNF-alpha and IL-1β in 0.1% 370 
(w/v) bovine serum albumin carrier protein (R&D Systems, Minneapolis, MN, USA) were 371 
reconstituted in phosphate buffered saline prior to use. The total amount of protein in each 372 
sample was quantified by the bicinchoninic acid assay (BCA, Thermo-Fisher, Waltham, MA, 373 
USA) per the manufacturer’s protocol using a bovine serum albumin standard curve, and a BCA 374 
reagent incubation time of 30 minutes at 37oC.   375 
FRANC Assay Method 376 
Sulfo-NHS-LC-Biotin (sulfosuccinimidyl-6-[biotin-amido]hexanoate, Thermo-Fisher, 377 
Waltham, MA, USA, Supplementary Figure 1) was incubated with 10 µg of protein sample at a 378 
mass ratio of 32:1 sample protein:Sulfo-NHS-LC-Biotin for 1 hour at room temperature. These 379 
biotinylated samples were diluted as desired and loaded into 96 well plates (50µL sample per 380 
well). Streptavidin-coated hydrophobic magnetic microbeads (Dynabeads MyOne Streptavidin 381 
T1 [10mg/mL], Thermo-Fisher, Waltham, MA, USA) of 1.05 µm diameter were washed twice 382 
with 0.5% (v/v) TweenTM-20 (Fisher Scientific, Waltham, MA, USA) phosphate buffered saline 383 
(referred to as T-PBS) by adding 1mL of T-PBS to 12µL of microbeads and subsequent 384 
microbead removal from solution using a neodymium bar magnet (0.75” length x 0.25” width x 385 
0.25” height, 10.5 lbs pull force, K&J Magnetics, Pipersville, PA, USA). Microbeads were then 386 
resuspended in T-PBS at 20µg/mL (500 dilution factor) and 50 µL of bead suspension was 387 
added to each protein sample. Protein samples and microbeads were then allowed to incubate 388 
for 30 minutes at room temperature.  389 
After incubation, microbeads were magnetically removed from suspension using a 390 
custom-made 96 well magnetic plate separator (Supplementary Figure 1, 96 ¼” diameter x ½” 391 
thick cylindrical magnets assembled in a 96-well plate, 4.8 lbs. pull strength for each magnet, 392 
K&J Magnetics, Pipersville, PA, USA). Specifically, the 96-well plate was placed on top of the 393 
magnetic separator for 30 seconds, after which the solution was removed from each well by 394 
inverting the plate over a waste reservoir. Microbeads were washed twice with 100µL of T-PBS 395 
and incubated with 50µL of the appropriate antibody solution for 30 minutes at room 396 
temperature, followed by washing with T-PBS.  397 
To detect all proteins in the sample (“total protein”) by carbodiimide crosslinking, 50µL of 398 
1 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, MilliporeSigma, St. Louis, MO, 399 
USA, Supplementary Figure 6) and 2.5 mM N-hydroxysulfosuccinimide (sulfo-NHS, 400 
MilliporeSigma, St. Louis, MO, USA, Supplementary Figure 6) in T-PBS were added to 401 
microbead suspensions and immediately agitated and incubated for 15 minutes at room 402 
temperature. Following two T-PBS washes, 50 µL of 50 µg/mL 4’-(aminomethyl) fluorescein 403 
(AMF, Thermo-Fisher, Waltham, MA, USA, Supplementary Figure 1) dye in T-PBS was added 404 
to the microbead suspension and incubated for 2 hours at room temperature under agitation. 405 
After 2 additional T-PBS washes, microbeads were resuspended in 200 µL T-PBS and analyzed 406 
by flow cytometry (Attune NxT, 12.5ul/min, 25µl volume, Thermo-Fisher, Waltham, MA, USA). 407 
Confirming Magnetic Separation of Microbeads 408 
To confirm that microbeads were not washed away when immobilized by the external 409 
magnet during wash steps, microbeads were counted by flow cytometry before any wash steps 410 
and after each of three wash steps. 50 µL of diluted microbeads (20µg/mL in T-PBS) were 411 
added to each well of a 96 well plate. Unwashed controls were immediately collected from the 412 
plate by pipetting and placed in 1.5 mL microtubes for subsequent flow cytometry analysis. The 413 
remaining microbead samples were washed three times with T-PBS, and samples were 414 
collected into 1.5 mL microtubes after each wash step.  415 
Determining Suitable Assay Conditions 416 
We extensively tested the effects of changing key assay parameters, e.g. concentrations 417 
of reagents and durations of key steps, in the FRANC assay. Starting (baseline) values for 418 
assay parameters and reagent concentrations were informed by protocols for related 419 
bioconjugation techniques20. For simplicity, rabbit serum was initially used as the protein 420 
sample, and we assayed the amount of rabbit immunoglobulin G (IgG) in the sample using a 421 
commercial fluorescent antibody (Donkey F[ab']2 Anti-Rabbit IgG – Phycoerythrin [PE], Abcam, 422 
Cambridge, United Kingdom)9,36,37.  Below we describe which assay protocol parameters were 423 
assessed, the justifications for baseline parameter values, and how tests were conducted.  424 
For each parameter, two key outputs were used to determine suitable assay conditions:  425 
the assay's operating range and its dynamic output range (DOR). The operating range was 426 
determined from plots of logarithmically transformed antibody-specific labeling (y-axis) vs. 427 
logarithmically transformed amount of sample protein (x-axis), and was defined as the largest 428 
possible sample protein region (x-axis) over which: (1) y-values were greater than vehicle-only 429 
controls, and (2) coefficient of determination values (R2) for linear regression of y on x were 430 
greater than 0.9. Log-log transformation was utilized to allow analysis of faint antibody signals 431 
and small protein loading amounts that are often under-weighted in traditional linear analysis. 432 
The DOR was defined as the maximum signal magnitude (y axis value) in the operating range 433 
divided by the signal (y axis value) for the vehicle-only controls.  434 
In addition, we carried out a similar analysis using total protein fluorescent signal as the 435 
quantity plotted on the y-axis to determine the operating range and DOR for total protein 436 
labeling. We then sought assay conditions resulting in a large operating range and a large DOR 437 
for both antibody-specific labeling and total protein labeling, since this maximized the assay’s 438 
ability to accurately detect quantitative differences between protein samples.  439 
Levels of biotinylation 440 
Higher levels of sample protein biotinylation may inhibit antibody-specific labeling, while 441 
lower biotinylation levels may lead to poor coupling of sample proteins to streptavidin-coated 442 
beads. Thus, it was important to determine a suitable level of biotinylation. Previous studies 443 
have suggested that molar biotin:protein ratios of less than 5:1 reduce protein aggregation, 444 
insolubility, and inhibition of antibody-labeling 20. Furthermore, biotin:protein ratios as low as 2:1 445 
have been shown to result in effective streptavidin binding 38. However, the use of molar ratios is 446 
impractical when using complex samples containing a mixture of proteins. Instead, we used 447 
mass ratios; assuming an average protein size of 53 kDa39, 2:1 and 5:1 biotin:protein molar 448 
ratios correspond to idealized protein:biotin mass ratios of approximately 45:1 or 18:1, 449 
respectively. The approximate mean of these two mass ratios, namely 32:1 protein:biotin, was 450 
used as a starting point for further testing. Mass ratios greater than and less than 32:1 were 451 
assessed to determine their effect on labeling of specific proteins and on total protein labeling.  452 
Rabbit serum was incubated with biotin for 1 hour at protein:biotin mass ratios from 453 
2048:1 to 0.5:1, or without biotin. Biotinylated rabbit serum samples were then loaded into 96 454 
well plates using the following serial dilution structure: 8 µg protein/well, 4-fold serial dilutions 455 
from 2 to 1/8 µg protein/well, and 2-fold serial dilutions from 1/16 to 1/1024 µg protein/well. 456 
Streptavidin-coated microbeads were then added to each well for 30 minutes to conjugate 457 
protein.  Next, antibody-specific labeling was performed with a fluorescently (PE fluorophore) 458 
conjugated anti-IgG antibody. The operating range and DOR were determined for each 459 
protein:biotin mass ratio.  460 
After determining the preferred protein:biotin mass ratio, biotin-protein incubation 461 
durations of 15, 30, 60, and 120 minutes were tested, using an approach as described above. 462 
The operating range and DOR were determined for each incubation time. 463 
Protein-microbead incubation duration 464 
Next, we investigated the effect of incubation duration for biotinylated proteins with 465 
microbeads, considering incubation durations from 30 minutes to overnight. For this purpose, 466 
we used rabbit serum samples, diluted into 96-well plates, detected with antibodies against IgG, 467 
as described above. The operating range and DOR were determined for each incubation time.  468 
Antibody labeling 469 
To optimize antibody labeling, we used rabbit serum protein as the sample and an anti-470 
IgG antibody, as described above. We first considered the effect of antibody concentration, 471 
testing antibody concentrations from 10ug/mL (50 DF for the antibody) to as little as 472 
approximately 5ng/mL (10240 DF). We then examined the effect of antibody incubation 473 
duration, considering durations from 30 minutes to 120 minutes. The operating range and DOR 474 
were determined for each incubation duration.  475 
Total protein labeling 476 
Fluorescent labeling of the total protein conjugated to microbeads in each sample is 477 
necessary for normalization as an integral part of the FRANC assay. Since primary amine 478 
groups were utilized for protein biotinylation, carboxylic acid residues, found in glutamic and 479 
aspartic acid amino acids as well as the protein C-terminus, were targeted for this purpose39. 480 
Specifically, a carbodiimide crosslinker was used to conjugate a primary amine-containing 481 
fluorescent dye to carboxylic acid residues (Figure 3C). To minimize hydrolysis and subsequent 482 
loss of reactivity of the unstable acylisourea intermediate formed after reaction with EDC, sulfo-483 
NHS was added with EDC to form a more stable sulfo-NHS-ester intermediate (Figure 3C)20. 484 
Immediately following formation of the sulfo-NHS-ester intermediate, primary amine-containing 485 
fluorescent dye was added to label the amine-reactive intermediate. In order to minimize 486 
microbead aggregation due to amine-reactive sulfo-NHS intermediates binding available 487 
primary amine sites on proteins and the microbead surface, carbodiimide crosslinking and 488 
fluorescent labeling were performed with intense agitation.  489 
The following parameters were varied to determine their impact on total protein labeling: 490 
EDC concentration, sulfo-NHS concentration, crosslinking (EDC + sulfo-NHS) duration, amine-491 
reactive fluorescent dye type and concentration, and dye incubation duration. For each 492 
condition, biotinylated rabbit serum attached to microbeads was used without antibody labeling. 493 
The operating range and DOR for total protein labeling were determined for each parameter. 494 
Baseline values for EDC concentration (1mM), sulfo-NHS concentration (2.5mM), and 495 
crosslinking duration (15 minutes) were selected based on previous studies 20. We tested EDC 496 
concentrations of 10 mM, 1mM, 0.1mM, and 0.01mM. 10mM EDC resulted in substantial 497 
microbead aggregation and was thus not further considered (data not shown). We tested sulfo-498 
NHS concentrations of 25mM, 2.5mM and 0.25mM, in conjunction with the preferred EDC 499 
concentration. We then tested crosslinking durations of 15 and 30 minutes, using the preferred 500 
sulfo-NHS and EDC concentrations. We reasoned that any primary amine-containing dye 501 
should be compatible with carbodiimide crosslinking and thus Alexa Fluor 488 hydrazide was 502 
arbitrarily chosen as the first dye to be tested, at a concentration of 5µg/mL, based on the 503 
manufacturer’s suggestions. For cost reasons, higher concentrations of the Alexa Fluor 488 504 
hydrazide were not tested. Instead, 4’-(aminomethyl) fluorescein (Thermo-Fisher, Waltham, MA, 505 
USA, Supplementary Figure 6), an alternative primary amine-containing fluorescent dye, was 506 
tested at concentrations of 5 µg/mL, 50 µg/mL and 500 µg/mL. The preferred dye type and 507 
concentration were then tested for incubation times of 30 minutes, 1 hour, 2 hours, and 4 hours.  508 
FRANC Assay Analytical Sensitivity 509 
To determine the analytical sensitivity of the FRANC assay, recombinant proteins of 510 
known concentrations were used. Human recombinant TNF-α was conjugated to microbeads 511 
over a 24-step protein dilution curve, with 2-fold dilutions at each step, and microbeads at each 512 
dilution were exposed to an anti-TNF-α fluorescently-conjugated (PE-Cy7) primary antibody 513 
(eBioscience, Waltham, MA, USA). Similarly, we tested human recombinant IL-1β, with the 514 
exception that a non-fluorescent anti-IL-1β primary antibody (eBioscience, Waltham, MA, USA) 515 
was used followed by three T-PBS wash steps and fluorescent (PE) secondary antibody 516 
labeling (Abcam, Cambridge, United Kingdom). Operating regions were determined as above, 517 
and the smallest protein amount within the operating region for which the fluorescent signal was 518 
greater than the signal from vehicle-only controls was identified as the FRANC assay sensitivity. 519 
Three technical replicates were carried out for each recombinant protein type.  520 
Comparing total protein labeling for different protein samples 521 
We next sought to determine how consistent total protein labeling (quantification) was 522 
between different samples. Quantification of total protein signal is inherently challenging due to 523 
variation in amino acid composition across different proteins. If the labeling chemistry is highly 524 
sensitive to amino acid structure, different proteins will be “weighted” differently during 525 
quantification, resulting in differences between protein sample types. As a comparison for the 526 
FRANC assay, total protein labeling results were compared to those from the widely-used 527 
bicinchoninic acid (BCA) assay. However, even the BCA assay is known to give results that 528 
vary between protein sample types22. Thus, the goal for the FRANC assay’s total protein 529 
quantification was to demonstrate inter-sample variability similar (or less than) to the BCA 530 
assay.  531 
 Goat, rabbit, and mouse sera, as well as cell lysates (mesenchymal stem cells, HT-532 
1080 cells treated with PMA, and HT-1080 untreated cells) were biotinylated, conjugated to 533 
microbeads, and then diluted into 96 well plates (2-fold serial dilution over 11 steps). Total 534 
protein labeling was performed, followed by flow cytometric analysis. The operating regions (R2 535 
> 0.90) from plots of total protein fluorescent labeling vs. loaded protein amount were 536 
determined for each sample type, as described above. Ideally, if all proteins samples were 537 
measured identically by the total protein labeling, the resulting slopes for each sample’s 538 
operating range would be equal, whereas any deviation in slope values would suggest that the 539 
amino acid composition of the assayed proteins influenced the total protein labeling intensity.  540 
For comparison, the same methodology was utilized with the BCA assay. Each protein 541 
sample was prepared for the BCA assay and sample absorbance was measured using a 542 
microplate reader (Bio-Tek Synergy H4, Winooski, VT, USA). Results were analyzed similar to 543 
total protein labeling, as described above, for each sample. However, the traditional methodology 544 
for determining the BCA assay operating range uses linear regression without the log-log 545 
transformations used when analyzing the FRANC assay. To ensure a balanced comparison, BCA 546 
and FRANC assay results were analyzed using both methods. The BCA reagent absorbance was 547 
plotted vs. standardized sample concentration, and the slope of the linear region was determined. 548 
The variability of slope values for the BCA assay was compared to the variability of slope values 549 
from the FRANC assay’s total protein labeling to determine the FRANC assay’s performance.  550 
FRANC Assay Normalization Capabilities  551 
Finally, the normalization capabilities of the FRANC assay were tested using rabbit 552 
serum as the protein sample. Biotinylated rabbit serum over a range of concentrations was 553 
conjugated to microbeads, and antibody labeling was performed for each microbead sample, 554 
followed by total protein labeling.   Antibody labelling and total protein labelling values over the 555 
concentration range were obtained by flow cytometry, and the operating range was determined 556 
for antibody signal vs. loaded sample protein amount. We then normalized the antibody-specific 557 
protein signal by the total protein signal across the operating range. The slope of the log-log 558 
transformed antibody signal vs. loaded sample protein amount was calculated with and without 559 
total protein normalization to determine whether normalization reduced the experimental 560 
variability, since a slope closer to 0 implies that the antibody signal is less sensitive to the 561 
loaded sample amount. Further, antibody signal across the operating range was normalized 562 
relative to actual loaded protein amount, as determined separately by the BCA assay, to 563 
compare FRANC assay performance to BCA normalization. 564 
Statistics 565 
To evaluate treatment effects between 3 or more experimental groups, ANOVA was 566 
used. The normality of distributions, required for use of ANOVA, was assessed using the 567 
Shapiro-Wilk test, with a rejection threshold of p < 0.05. To assess whether variances were 568 
equal between groups, also required for ANOVA, we used the Brown-Forsythe test, with a 569 
rejection threshold of p < 0.05. When ANOVA was suitable, Tukey’s post hoc test was used to 570 
compare all groups or Dunnett’s post hoc test was used to compare each group mean to a 571 
single control mean, where p < 0.05 indicated significant differences. 572 
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